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CAP = community-acquired pneumonia; IL = interleukin.
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Abstract
Recent studies have suggested that combination antibiotic therapy
is preferable to monotherapy for severe community-acquired
pneumonia (CAP). In this issue Mortensen and colleagues present
retrospective data suggesting that combination therapy with a
cephalosporin and a fluoroquinolone is inferior to combination
therapy with a cephalosporin and a macrolide. Several mechanisms
exist by which quinolones could be inferior to macrolides in
combination therapy, so if these findings are confirmed by other
groups they have significant implications for physicians treating
patients with severe CAP.
In the past 5 years there has been a substantial shift in
thinking regarding the optimal therapy of patients with severe
community-acquired pneumonia (CAP), particularly with
respect to pneumococcal disease. Observational studies by
Mufson and Stanek [1], Waterer et al. [2], Martinez et al. [3],
Baddour  et al. [4] and Weiss et al. [5] have all identified
significant mortality reductions in patients with bacteraemic
pneumococcal pneumonia who received combination
antibiotic therapy in comparison with patients who received
monotherapy. Additional observational studies in more
general CAP cohorts have also identified outcome benefits of
combination therapy over monotherapy [6-9].
Despite the limitations of these primarily retrospective
observational studies, the similar findings in different
populations makes it very likely that the association is real.
However, it remains unclear whether there is a true survival
advantage of combination therapy or whether there are
common confounding factors related to patient selection, to
the process, to quality or to care.
In this issue, Mortensen et al. [10] demonstrate that, at least
in their region, physicians have widely adopted combination
therapy in patients with severe CAP. In contrast with previous
studies, an important strength is that a large proportion of
patients were intubated by severe respiratory failure. The
findings of Mortensen et al. that fluoroquinolone/β-lactam
combinations were associated with worse outcome than
other combination regimens is both enlightening and
disturbing.
The most consistent finding across the retrospective studies
favouring combination therapy is that it is the addition of a
macrolide to a third-generation cephalosporin that has the
best outcome [1-3,6,7,9]. What is not clear is the mechanism
by which the addition of a macrolide is beneficial. Possible
explanations include coverage of unrecognized co-infection
with atypical pathogens, non-ribosomal anti-pneumococcal
activity such as impairment of epithelial adherence [11], and
their increasingly used immunomodulatory actions [12]. The
findings of Mortensen et al. [10], if proved correct, indicate
that coverage of atypical pathogens is not the mechanism of
benefit because there is no evidence that fluoroquinolones
are inferior to macrolides for these pathogens and may even
be superior [13].
Assuming that the findings of Mortensen et al. [10] are real and
can be replicated by other groups, what possible explanations
are there for the poor performance of fluoroquinolone/β-lactam
combinations? First, it is important to remember that this was
not a study of single compared with combination antibiotic
therapy. No data were presented that suggested that the
combination of a β-lactam and a fluoroquinolone is worse than
either agent separately and there is no in vitro evidence of
antagonism between these classes of antibiotics. However,
one potential adverse impact of the much broader spectrum of
coverage provided by a fluoroquinolone/β-lactam combination
Commentary
Choosing the right combination therapy in severe 
community-acquired pneumonia
Grant W Waterer1 and Jordi Rello2
1Associate Professor of Medicine, School of Medicine and Pharmacology, University of Western Australia, MRF Building, Royal Perth Hospital, GPO
Box X2213, Perth 6847, Australia
2Chief and Professor of Medicine, Critical Care Department, Joan XXIII University Hospital.Carrer Dr. Mallafre Guasch, 4.43007 Tarragona, Spain
Corresponding author: Grant W Waterer, waterer@cyllene.uwa.edu.au
Published: 24 January 2006 Critical Care 2006, 10:115 (doi:10.1186/cc3976)
This article is online at http://ccforum.com/content/10/1/115
© 2006 BioMed Central Ltd
See related research by Mortensen et al. in this issue [http://ccforum.com/content/10/1/R8]Page 2 of 3
(page number not for citation purposes)
Critical Care    Vol 10 No 1 Waterer and Rello
is the selection of highly resistant nosocomial (hospital-
acquired) pathogens, particularly Pseudomonas aeruginosa,
which is the first cause of superinfection in intubated patients.
Although no data on nosocomial infections were presented by
Mortensen et al. [10], it is notable that the survival graph shows
a continued disadvantage of initial fluoroquinolone/β-lactam
combination therapy well beyond 7 days and into the time
frame in which nosocomial sepsis would be expected to
contribute to mortality.
A second possibility, put forward by Mortensen et al. [10], is
that their findings favouring macrolides are due to the
immunomodulatory properties of this class of antibiotics. In
healthy subjects macrolides substantially reduce the in vitro
pro-inflammatory response to infectious stimuli, including the
key cytokines tumour necrosis factor, IL-1β, IL-6 and IL-8 [12].
However, the reduction in immune response is not global, with
minimal to no change in response to interferon-γ [14], a key
cytokine in the restoration of immune function after sepsis-
induced immunoparalysis. Macrolides have also been reported
to downregulate the production of reactive oxygen species,
blocking the activation of nuclear transcription factors,
inhibiting neutrophil activation and mobilization, accelerating
neutrophil apoptosis, and improving the clearance of mucus
[15,16]. In contrast to macrolides, quinolones seem to have a
more global immunosuppressive effect [17], including
significant impairment of interferon-γ production [14]. The
combination of selection for multiresistant pathogens and
potential prolongation of post-sepsis immunoparalysis
certainly could explain the survival disadvantage observed with
fluoroquinolones in comparison with macrolides.
All the potential explanations for the findings of Mortensen et
al. [10] are worth exploring, but only if prospective,
randomized, double-blind trials confirm the benefit of
combination therapy in pneumococcal disease, including a
clear benefit of having a macrolide as part of the combination.
For a disease as common as CAP, with a mortality rate
approaching or exceeding 20% in severe disease, it is
unacceptable that the present level of uncertainty about
optimal therapy exists. The large number of different
combinations chosen by physicians in the study by
Mortensen et al. [10] is a clear indication that the therapeutic
uncertainty in severe CAP is perceived by physicians at the
‘front line’. Indeed, other studies [18-20] have suggested that
a substantial proportion of clinicians select the empirical
antibiotic regimen by using a patient-based policy rather than
by following general guidelines. Now that there is a strong
suggestion that fluoroquinolones may be suboptimal
compared with macrolides as one arm of combination therapy
in severe CAP, conducting prospective, randomized clinical
trials including a large proportion of Pneumonia Severity
Index of V patients should be a priority.
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